Talampanel

From WikiMD.org
Jump to navigation Jump to search

Talampanel

Talampanel (pronounced ta-LAM-pan-el) is a non-competitive AMPA receptor antagonist that was under development for the treatment of various neurological disorders, including epilepsy and ALS.

Etymology

The term "Talampanel" is derived from the chemical name of the drug, which is 2,3-dihydro-1H-pyrrolo[3,4-b]quinolin-1-one. The name is a combination of parts of the words "pyrrolo", "quinolin", and "one".

Usage

Talampanel was investigated for its potential use in the treatment of epilepsy and ALS. It works by blocking the action of the neurotransmitter glutamate, which is known to cause neuronal damage when present in excessive amounts. However, the drug did not progress beyond phase II clinical trials due to lack of efficacy.

Related Terms

  • AMPA receptor: A type of ionotropic transmembrane receptor for glutamate that mediates fast synaptic transmission in the central nervous system.
  • Glutamate: An important neurotransmitter that plays a key role in long-term potentiation and is important for learning and memory.
  • Epilepsy: A neurological disorder marked by sudden recurrent episodes of sensory disturbance, loss of consciousness, or convulsions, associated with abnormal electrical activity in the brain.
  • ALS: A specific disorder that involves the death of neurons controlling voluntary muscles.

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski